A human cell beryllium acute toxicity assay.
A rapid, inexpensive beryllium acute toxicity assay using human erythrocyte ATP levels has been developed. The assay uses a photometric measurement of the luciferin-luciferase reaction in erythrocytes incubated in HEPES buffer with the tested toxicant. Incubation in HEPES significantly increases the sensitivity of erythrocytes to beryllium when compared to incubation in either plasma or physiological saline. After a one-hour incubation period in HEPES buffer and beryllium there is a loss of 50% of the erythrocyte ATP at 3 micrograms/ml of beryllium, and an 80% loss of ATP at 5 micrograms/ml of beryllium. The source of human erythrocytes does not appear to influence the test. Erythrocytes from 10 individuals, one with chronic beryllium disease and another with an acute sensitivity to beryllium, all gave similar biphasic dose-response curves to beryllium.
Clarke
S M
SM
Rockwell International Corporation, Golden, Colorado 80402-0464.
Barrick
C W
CW
D000255:Adenosine Triphosphate / Q000097:blood; D001607:Berylliosis; D001608:Beryllium / Q000633:toxicity*; D004912:Erythrocytes / Q000187:drug effects*; D006801:Humans; D006863:Hydrogen-Ion Concentration; D066298:In Vitro Techniques; D009784:Occupational Diseases / Q000097:blood / Q000139:chemically induced; D009997:Osmotic Pressure
D000255:Adenosine Triphosphate; D001608:Beryllium